Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Natural Alternatives

This article was originally published in The Tan Sheet

Executive Summary

San Marcos, Calif.-based supplement firm's net sales increased 45% to $23.3 mil. in the fiscal fourth quarter (ended June 30). For the year, net sales totalled $78.5 mil., up 40%, and income jumped to $3 mil, up 171%. Year-end results for the fiscal year included a 50% increase in private label contract manufacturing sales. Natural Alternatives "invested heavily" in facilities and equipment in fiscal 2004 and "will continue those investments in fiscal 2005," according to President Randell Weaver...

You may also be interested in...

Natural Alternatives

San Marcos, Calif.-based supplement firm reports sales increase of 36% to $22.7 mil. with earnings up 50% to $852,000 in the first fiscal quarter. CEO Mark Le Doux said sales are in line with fiscal 2005 growth plans, and that Natural Alternatives is "beginning to see brand preference develop" in its contract manufacturing business. In its last earnings call, the firm maintained it will continue investments in facilities and equipment throughout the fiscal year (1"The Tan Sheet" Sept. 29, 2004, In Brief)...

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts